Methylation testing

Methylation testing

DNA testing that detects if a gene is active or imprinted.
Mentioned in: Prader-Willi Syndrome
Mentioned in ?
References in periodicals archive ?
Methylation testing of the patient's DNA compared with a control DNA.
Terhaar Sive Droste et al., "Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection," Cellular Oncology (Dordrecht), vol.
Therefore, it would be logical to combine SHISA3 methylation testing with other methylation biomarkers.
She finds that she enjoys speaking with physicians and nurses about a vast array of tests, ranging from DNA methylation testing for Prader-Willi/Angelman Syndrome to immunodiffusion testing for Aspergilllus antibodies.
MLH1 methylation testing requires specific analysis of CpG islands in the proximal promoter region because other regions do not correlate as well with loss of MLH1 expression.
6 January 2010 - Belgian molecular diagnostics company OncoMethylome Sciences (EBR: ONCOB) said today it will perform MGMT gene promoter methylation testing in a Phase III clinical trial of Avastin in newly diagnosed brain tumours.
Initially, syndrome-specific methylation testing for PWS and AS would be ordered along with copy number and single-nucleotide polymorphism microarray analysis for diag nosis and establishing the genetic subtype (deletion, uniparental disomy, or imprinting defect).
(7) Methylation testing is more technically challenging than BRAF mutation testing is, so many pathologists have chosen BRAF testing as the more cost-effective clinical assay to distinguish sporadic from familial MSI-H CRC.
Hoffmann-La Roche Ltd, a division of the biotech company Roche, for MGMT gene promoter methylation testing in a Phase III clinical trial for the use of Avastin in newly diagnosed glioblastoma (GBM) brain tumours.
Although real-time PCR-based methylation testing for FXS is available (12) and is specific for FXS males carrying the FM with a methylated FMR1 CpG island located 5' of the expansion, there is currently no real-time PCR-based test that can be used to predict specific cognitive and behavioral impairments in female carriers with expanded FMR1 alleles.
Molecular diagnostics company OncoMethylome Sciences (Euronext Brussels:ONCOB) (Euronext Amsterdam:ONCOA) declared on Wednesday that it has signed an agreement for MGMT gene promoter methylation testing in a Phase III clinical trial for the use of Avastin in newly diagnosed (glioblastoma [GBM]) brain tumours.